Retatrutide 20mg

Retatrutide (LY3437943) represents the frontier of metabolic pharmacology as the first triple agonist combining synchronized activation of GIP, GLP-1, and glucagon receptors. This acylated synthetic peptide (MW: ~5960 Da) incorporates:

Innovative Molecular Design:

• Base structure: optimized sequence of human glucagon peptide
• Strategic modifications for balanced tri-agonist activity
• C18-C20 acyl chain at a specific lysine residue (albumin binding >98%)
• Hydrophilic spacer for serum stability
• Resistance to DPP-4 and neprilysin degradation

Triple Synergistic Mechanism of Action:

1. GIP-R Activation (Glucose-dependent insulinotropic polypeptide):

• Potentiation of glucose-dependent insulin secretion
• Lipid Metabolism Modulation in White Adipocytes
• Anti-inflammatory effect in adipose tissue
• Neuroprotection in the CNS

2. GLP-1R Activation (Glucagon-Like Peptide-1):

• Insulin secretion + glucagon suppression
• Delayed gastric emptying (reduction 75%)
• Appetite suppression via hypothalamic nuclei
• Preservation of pancreatic beta cells

3. Glucagon Receptor Activation (GCGR):

• Paradoxical effect Increase in energy consumption 15-20%
• Hepatic lipolysis: visceral/ectopic fat mobilization
• Thermogenesis in brown adipose tissue (BAT)
• Prevention of hepatic steatosis (↑ beta-oxidation)

Unique Pharmacokinetics

• SC Bioavailability: 75–82%
• Max T: 24-48 hours
• Average lifespan: 6-7 days (168 hours)
• Steady state: 5-6 weeks
• Elimination: enzymatic degradation + renal clearance <2%

Weight Loss Data in Comparative Research

Phase 2 Studies (Dose Escalation):

• Body weight reduction: up to 24.2% at a dose of 12 mg (48 weeks) (Jastreboff et al., 2023)
• Comparison: 15% semaglutide 2.4 mg, 20% tirzepatide 15 mg
• Weight loss ≥20%: 75% participants (maximum dose)
• Weight loss ≥25%: 45% participants

Revolutionary Body Recomposition:

• Visceral fat: 50–60% reduction (abdominal MRI)
• Fatty liver: decrease of 70–80% (NMR spectroscopy)
• Lean body mass: preservation 93-96% (greater than caloric restriction)
• Resting energy expenditure: increase of 8–121 TP3T compared to baseline

Metabolic and Cardiometabolic Effects

Glycemic Control

• HbA1c Reduction: 2.5–3.01 TP3T in People with Type 2 Diabetes
• Time in range (70–180 mg/dL): improvement from 80 to 921 TP3T
• Glycemic variability: reduction 40%
• Reversal of Prediabetes: 85% Patients

Complete Lipid Profile

• Triglycerides: ↓ 35–40%
• LDL cholesterol: ↓ 15–20%
• HDL cholesterol: ↑ 12–18%
• Apolipoprotein B: ↓ 25%
• Small LDL particles: 50% reduction

Cardiovascular Health:

• Systolic blood pressure: ↓ 10-15 mmHg
• Diastolic: ↓ 5-8 mmHg
• Arterial stiffness: improvement in the aortic index 20%
• Endothelial function: ↑ flow-mediated vasodilation 35%

Thermogenesis and Energy Expenditure

Brown Adipose Tissue (BAT) Activation:

• PET-CT glucose uptake: 250% increase in BAT
• UCP1 (thermogenin) expression: 180% increase
• Supraclavicular region temperature: +0.8-1.2°C
• Fatty acid oxidation: increase in 45%

“Browning” White Adipocytes:

• Expression of thermogenic genes (PRDM16, PGC-1α): ↑ 200%
• Mitochondriogenesis: mitochondrial density +60%
• Cellular respiration: O₂ consumption +55%

Clinical Research Evidence: Weight and Mood

Meta-Analysis Weight Loss Interventions:

Lassale et al. (2019) – The Lancet Psychiatry:

• 15 studies, n=3,064 patients
• Weight loss ≥5%: reduction in depressive symptoms, SMD -0.58 (95% CI %: -0.82 to -0.34)
• Weight loss ≥10%: SMD reduction of -0.94 (large effect)
• Dose-response relationship: every additional 5% loss → 0.3 SD improvement on depression scales

Fabricatore et al. (2011) – Obesity:

• Weight loss 10–15%: remission of major depression 40–55% vs. 15% controls
• Mental Quality of Life (SF-36): Improvement of 12-18 points (clinically significant >5)
• Beck Depression Inventory: reduction in 35-45% score

Specific Studies GLP-1 Agonists (Retatrutide Analogues):

Semaglutide – STEP 1 Study (Secondary Mental Health Analysis):

• PHQ-9 (Patient Health Questionnaire): 3.2-point reduction vs. 1.1 placebo
• Moderate-to-severe depression (PHQ-9 ≥10): remission 52% vs. 28% placebo
• Correlation: every 5kg weight loss → -1.5 PHQ-9 points
• Independent effects: 40% improves weight loss, 60% provides additional mechanisms

Tirzepatide – SURMOUNT-1 (Mental Health Outcomes):

• Baseline depression (self-reported): 22% participants
• Improves depressive symptoms: 68% tirzepatide group vs. 43% placebo group
• Health-Related Quality of Life: Improvement in Emotional Domains 25-35%
• Comorbid anxiety: reduction in 40% symptoms

Retatrutide Projections (Based on Significant Weight Loss):

Since Retatrutide results in weight loss of 24.2% (greater than competitors):

• Expected reduction in depression: 50-65% symptoms (dose-response extrapolation)
• Major depression referral: Estimated 60–70% mild-to-moderate cases
• Improve quality of life SF-36 mental component +15-22 points

Response time: Detectable improvements 8-12 weeks, maximum 24-36 weeks

Stratified Preclinical Dosage

Multicellular In Vitro Studies

Experimental Systems:

• 3T3-L1 adipocytes: 10-100 nM (lipolysis, thermogenesis)
• Primary hepatocytes: 5-50 nM (β-oxidation, gluconeogenesis)
• Pancreatic β-cells (INS-1): 1-10 nM (insulin secretion)
• C2C12 myotubes: 10-50 nM (glucose uptake, metabolism)

Thermogenic Analysis

• Cultivate immortalized brown adipocytes
• O₂ Consumption Measurement (Seahorse XF Analyzer)
• UCP1 Quantification by Western blot/immunofluorescence
• Mitochondrial morphology analysis (electron microscopy)

Maximum Stability Protocol:

1. Certified sterile environment (ISO 5 or higher)
2. Research grade bacteriostatic water (USP), pH 7.2-7.4
3. For a 2mg vial: add 0.8mL → 2.5mg/mL
4. Vial 5mg: add 2.0mL → 2.5mg/mL
5. Vial 20mg: add 4.0mL → 2.5mg/mL
6. Ultra-slow injection (30 seconds) at a 45° angle along the wall
7. Don't invest; rotate horizontally 60-90 seconds
8. Rest for 5 minutes at room temperature before use

Critical Storage

• Lyophilized: -80°C ideal (36 months stability); -20°C acceptable (24 months)
• Reconstituted: 2-8°C strictly, maximum 14 days
• Mandatory light protection: amber vials + opaque container
• Recommended individual portions (avoid refreezing)
• DO NOT freeze the reconstituted solution (40–60% loss of activity)

How does Retatrutide justify the inclusion of glucagon activity? A: Paradoxically, glucagon promotes weight loss by increasing energy expenditure by 15–20% and hepatic lipolysis, while GIP/GLP-1 prevent hyperglycemia. This unique synergy cannot be achieved with dual agonists.

Is it safe in models with liver impairment? A: Studies show improved liver function (↓ ALT/AST 40%, reduction in fibrosis from F3 to F1) in experimental NASH. Glucagon activation increases hepatic β-oxidation without toxicity (Sanchez-Garrido et al., 2023).

What is the optimal protocol to assess BAT thermogenesis? PET-CT with ¹⁸F-FDG after controlled cold exposure (16-18°C, 2h); supraclavicular tissue biopsy for UCP1/PGC-1α analysis; infrared thermography of the interscapular region; 24h indirect calorimetry.

Therapeutic window versus adverse effects? A: Wide therapeutic range: effective doses of 0.1–0.5 mg/kg in rodents show excellent tolerability. Transient nausea (first week) in 15–25% cases; resolves spontaneously. Monitor cardiac function at supratherapeutic doses (>3x).

Direct comparison with bariatric surgery in models? A: Retatrutide 12 mg (replica 85-90%) provides metabolic benefits comparable to those of Roux-en-Y gastric bypass without surgery: comparable weight loss, similar resolution of diabetes (80% vs. 85%), and equivalent improvement in lipid profile.

1. Jastreboff AM, et al. (2023) “Triple G Protein-Coupled Receptor Agonist Retatrutide for Obesity” – The New England Journal of Medicine389(6):514-526. [PubMed: 37355123]
2. Rosenstock J, et al. (2023) “Retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in type 2 diabetes” – The New England Journal of Medicine 389(6):503-513. [PubMed: 37272513]
3. Sanchez-Garrido MA, et al. (2023) “GLP-1/glucagon receptor co-agonism for the treatment of obesity” – Diabetology66(7):1281-1294. [PubMed: 37093254]
4. Coskun T, et al. (2022) “LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist” – Cell Metabolism34(9):1234-1247. [PubMed: 35952662]
5. Eli Lilly Research (2023) “Pharmacology and efficacy of retatrutide” – Diabetes Obes Metab 25(4):944-956.

This browser does not support iframes. You can download the PDF here:
Download PDF.

This browser does not support iframes. You can download the PDF here:
Download PDF.